Rooban Thavarajah Prof, Elizabeth Joshua Prof, U. R. Prof, Kannan Ranganathan Prof
{"title":"药物相关的唾液腺改变-风险评估","authors":"Rooban Thavarajah Prof, Elizabeth Joshua Prof, U. R. Prof, Kannan Ranganathan Prof","doi":"10.33882/JIDA.13.24723","DOIUrl":null,"url":null,"abstract":"Brief Background\nMedication Associated Salivary Gland Alterations (MASGA) are a common set of adverse events (AE) associated with many common medications. There are a few reports of the risk of MASGA with medication.\n\nMaterials and Methods\nUsing whole database approach, the Food and Drug Administration Adverse Event Reporting System (FAERS) of the United States of America was searched for MASGA. Common alterations and drugs associated were assessed for the Reporting Odds Ratio, as mentioned in pharmacovigilance researches.\n\nResults\nIn the time phase considered, there were in all 16996785 AE reported in the FAERs database. Of this 68624 were related to MASGA with Dry Mouth and hypersecretion\nbeing most common. Anti-psychotic drugs predominated the hypersecretion spectrum with clozapine having a ROR of 58.04 followed by Haloperidol (25.29). Among the drugs that caused SG enlargement, potassium iodide (1335.32) and Oxyphenbutazone (696.58) had the highest ROR. Non-specific description of altered saliva was seen with high ROR in haloperidol and enoxaparin sodium (14.22).\n\nSummary and Conclusions\nOdds Ratio of drugs causing MASGA are. chronic medication such as those given for non-communicable, life style diseases and psychiatric medications known to cause MASGA.\n\nKey Words\nSalivary Alterations, Xerostomia, Salivary gland enlargement, Adverse Events, Pharmacovigilance","PeriodicalId":76040,"journal":{"name":"Journal of the Indian Dental Association","volume":"7 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Medication Associated Salivary Gland Alterations– Assessment of risk\",\"authors\":\"Rooban Thavarajah Prof, Elizabeth Joshua Prof, U. R. Prof, Kannan Ranganathan Prof\",\"doi\":\"10.33882/JIDA.13.24723\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Brief Background\\nMedication Associated Salivary Gland Alterations (MASGA) are a common set of adverse events (AE) associated with many common medications. There are a few reports of the risk of MASGA with medication.\\n\\nMaterials and Methods\\nUsing whole database approach, the Food and Drug Administration Adverse Event Reporting System (FAERS) of the United States of America was searched for MASGA. Common alterations and drugs associated were assessed for the Reporting Odds Ratio, as mentioned in pharmacovigilance researches.\\n\\nResults\\nIn the time phase considered, there were in all 16996785 AE reported in the FAERs database. Of this 68624 were related to MASGA with Dry Mouth and hypersecretion\\nbeing most common. Anti-psychotic drugs predominated the hypersecretion spectrum with clozapine having a ROR of 58.04 followed by Haloperidol (25.29). Among the drugs that caused SG enlargement, potassium iodide (1335.32) and Oxyphenbutazone (696.58) had the highest ROR. Non-specific description of altered saliva was seen with high ROR in haloperidol and enoxaparin sodium (14.22).\\n\\nSummary and Conclusions\\nOdds Ratio of drugs causing MASGA are. chronic medication such as those given for non-communicable, life style diseases and psychiatric medications known to cause MASGA.\\n\\nKey Words\\nSalivary Alterations, Xerostomia, Salivary gland enlargement, Adverse Events, Pharmacovigilance\",\"PeriodicalId\":76040,\"journal\":{\"name\":\"Journal of the Indian Dental Association\",\"volume\":\"7 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-05-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Indian Dental Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33882/JIDA.13.24723\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Indian Dental Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33882/JIDA.13.24723","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Medication Associated Salivary Gland Alterations– Assessment of risk
Brief Background
Medication Associated Salivary Gland Alterations (MASGA) are a common set of adverse events (AE) associated with many common medications. There are a few reports of the risk of MASGA with medication.
Materials and Methods
Using whole database approach, the Food and Drug Administration Adverse Event Reporting System (FAERS) of the United States of America was searched for MASGA. Common alterations and drugs associated were assessed for the Reporting Odds Ratio, as mentioned in pharmacovigilance researches.
Results
In the time phase considered, there were in all 16996785 AE reported in the FAERs database. Of this 68624 were related to MASGA with Dry Mouth and hypersecretion
being most common. Anti-psychotic drugs predominated the hypersecretion spectrum with clozapine having a ROR of 58.04 followed by Haloperidol (25.29). Among the drugs that caused SG enlargement, potassium iodide (1335.32) and Oxyphenbutazone (696.58) had the highest ROR. Non-specific description of altered saliva was seen with high ROR in haloperidol and enoxaparin sodium (14.22).
Summary and Conclusions
Odds Ratio of drugs causing MASGA are. chronic medication such as those given for non-communicable, life style diseases and psychiatric medications known to cause MASGA.
Key Words
Salivary Alterations, Xerostomia, Salivary gland enlargement, Adverse Events, Pharmacovigilance